Burke J P, Pestotnik S L, Classen D C, Lloyd J F
Department of Clinical Epidemiology, LDS Hospital, Salt Lake City, UT 84143, USA.
Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):167-9. doi: 10.1016/0732-8893(95)00102-g.
A retrospective, matched cohort study was performed to determine the cost outcomes among 495 hospitalized patients who received twice-daily dosing of cefotaxime and 3949 matched cohorts who received other antibiotics. By an attribution model, twice-daily use was associated with shorter mean lengths of stay (-0.498 day, P < .7) and lower mean total costs of hospitalization (-$623, P < .8). Twice-daily dosing of cefotaxime is commonly employed for the treatment of a variety of serious infections, and appears to be cost effective.
进行了一项回顾性匹配队列研究，以确定495名接受每日两次头孢噻肟给药的住院患者与3949名接受其他抗生素治疗的匹配队列患者的成本结果。通过归因模型，每日两次给药与较短的平均住院时间（-0.498天，P < 0.7）和较低的平均住院总成本（-623美元，P < 0.8）相关。每日两次头孢噻肟给药常用于治疗各种严重感染，且似乎具有成本效益。
